Valiant Laboratories Ltd

The 50-day moving average has crossed above the 200-day for Valiant Laboratories Ltd, signalling a golden cross on 12 Jun 2026. Yet, the broader technical picture is conflicted, with weekly and monthly indicators sending mixed messages, and the stock’s micro-cap status adding a layer of caution to interpreting this signal.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 8 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

At Rs 69.27, Valiant Laboratories Ltd found itself locked at its lower circuit limit of 5% on 10 Jun 2026, with persistent selling pressure overwhelming demand and leaving unfilled supply on the exchange floor.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Valiant Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 20 May 2026, reflecting a complex interplay of improved quarterly financials but deteriorating quality and valuation metrics, alongside mixed technical indicators. Despite a positive financial trend in the latest quarter, concerns over long-term fundamentals and expensive valuation have weighed heavily on investor sentiment.

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from an already expensive rating to very expensive territory. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock has delivered mixed returns compared to the broader Sensex, prompting investors to reassess its price attractiveness amid challenging fundamentals and peer comparisons.

Valiant Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as sales and EBIT growth have strengthened considerably, concerns remain around returns and capital efficiency, prompting a cautious outlook despite the upgrade.

Valiant Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹432.00 crores, reported a net profit of ₹1.76 crores for Q4 FY26, marking a dramatic recovery from the ₹7.06 crore loss in the previous quarter. However, the apparent turnaround conceals troubling operational realities that warrant investor caution, with the stock declining 3.92% to ₹78.78 following the results announcement.

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s latest results reveal significant growth in revenue and profitability metrics, marking a positive shift from its previously flat financial trend and improving its Mojo Grade from Strong Sell to Sell.

Valiant Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 14 May 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s stock price rose 3.03% on the day following the upgrade, reflecting cautious optimism among investors amid flat financial performance and challenging long-term fundamentals.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 05 May 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

At Rs 77.57, sellers were still queuing — but there were no buyers willing to take the other side. Valiant Laboratories Ltd locked at its lower circuit of 5.0% on 30 Apr 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 24 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.